Company Overview and News
New Delhi, Infrastructure lender IFCI has recovered Rs 280.30 crore and has been allotted over 5.79 lakh equity shares of debt-ridden Bhushan Steel (BSL), which has been acquired by Tata Steel, under the insolvency process. “IFCI as one of the financial creditors to BSL had filed its claim with the resolution professional which was duly accepted. Under the resolution plan (RP) envisaging payment of Rs 35,200 crore to all the financial creditors, IFCI has since received its share of Rs 280.
Market regulator SEBI has zeroed in on two individuals who may have knowledge of perpetrators in the case relating to leak and circulation of sensitive financial details of a few companies and banks via WhatsApp. The two were the first to receive those messages before they were forwarded to others, a source told BusinessLine.
Infrastructure lender IFCI has recovered Rs 280.30 crore and has been allotted over 5.79 lakh equity shares of debt-ridden Bhushan Steel (BSL), which has been acquired by Tata Steel, under the insolvency process.
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday refused to entertain a second round of bidding for Bhushan Power and Steel Ltd, following a “suggestion” by the committee of creditors (CoC) of the debt-laden company.
New Delhi : Debt-ridden Bhushan Steel has sought 90 days extension to file its audited financial results for the quarter and year ended March 31, 2018. Tata Steel completed the acquisition of controlling stake of 72.65 per cent in the debt-laden firm last week. As per regulatory norms, the company is under obligation to submit its audited financial results for quarter and year ended March 31, 2018 within 60 days from the end of the financial year, that is by May 30, 2018.
Mumbai: The BSE Sensex rose over 187 points in early trade today, extending yesterday’s rally on robust buying in IT, energy and banking stocks amid unabated purchases by domestic institutional investors. Asian shares were mixed after US President Donald Trump cancelled a planned meeting with North Korean leader Kim Jong Un.
New Delhi: Debt-ridden Bhushan Steel, which has been acquired by Tata Steel under the insolvency process, has sought 90 days extension to file its audited financial results for the quarter and year ended 31 March 2018.
Market Update: The market held on to morning gains, with the Sensex rising around 150 points while the Nifty Midcap index extended rally, rising nearly 1.5 percent.
The broader are trading on a positive note on Friday morning, with the Nifty up 47 points at 10,561 and the Sensex gaining 151 points at 34,814.
Shares of IFCI advanced 10 percent intraday Friday as company received Rs 280 crore from Bhushan Steel resolution.
FRANKFURT/BERLIN: Activist hedge fund Elliott said on Thursday it would step up pressure on Thyssenkrupp's leadership to revive the German industrial conglomerate's fortunes, confirming it had taken a stake of less than 3 percent.
Frankfurt: Thyssenkrupp AG’s chief Heinrich Hiesinger is facing the fight of his career as a pair of activist investors take aim at the German industrial giant.
Market Closing: Benchmark indices after yesterday's breather resumed selling pressure again, with the Sensex losing more than 300 points on weaker rupee and global weakness.
Earnings: Archies has reported net profit of Rs 30.6 crore in the Q4FY18 against loss of Rs 1.6 crore in the same quarter last fiscal.
Earnings Reaction: GVK Power share price rallied 10 percent after the company reported profit at Rs 23.1 crore in March quarter 2018 against loss of Rs 205.8 crore in March quarter 2017.
16h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
17h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...